Oprah Winfrey on why she left WeightWatchers after admitting to weight loss drug use

Sign up to our free Living Well electronic mail for recommendation on dwelling a happier, more healthy and longer life

Live your life more healthy and happier with our free weekly Living Well e-newsletter

Oprah Winfrey has opened up about her choice to go away the WeightWatchers board.

The media mogul, 70, appeared on a latest episode of Jimmy Kimmel Live, the place she revealed that she resigned from her place on the board of WeightWatchers, after practically a decade, due to her upcoming particular about prescription weight loss drugs.

“I decided that, because this special was really important to me and I wanted to be able to talk about whatever I want to talk about, and WeightWatchers is now in the business of being a weight health company that also administers drug medications for weight,” Winfrey mentioned. “I did not want to have the appearance of any conflict of interest.”

The former speak present host admitted she resigned from the board because of her forthcoming TV particular, titled ​​“An Oprah Special: Shame, Blame and the Weight Loss Revolution”, which airs 18 March on ABC. She subsequently donated all of her shares within the firm to the National Museum of African American History and Culture.

“So, nobody can say: ‘Oh, she’s doing that special. She’s making money and promoting.’ No. You cannot say that,” Winfrey pressured. When the longtime spokeswoman was requested by Kimmel whether or not WeightWatchers cried when she introduced her resignation, the movie producer quipped: “They almost did.”

In February, Winfrey introduced that she was stepping down from her place on the WeightWatchers board. The Oscar winner first turned concerned with the corporate when she used its weight loss program for herself, earlier than buying a big stake and turning into a board member in 2015. In her assertion, Winfrey famous that she would proceed to be concerned within the message behind WeightWatchers.

“I look forward to continuing to advise and collaborate with WeightWatchers and CEO Sima Sistani in elevating the conversation around recognising obesity as a chronic condition, working to reduce stigma, and advocating for health equity,” she mentioned.

“Weight Health is a critically important topic and one that needs to be addressed at a broader scale. I plan to participate in a number of public forums and events where I will be a vocal advocate in advancing this conversation,” Winfrey added.

The announcement got here just some months after the billionaire revealed she was utilizing prescription weight loss remedy. While Winfrey didn’t identify the weight loss drug model, she nonetheless praised the remedy for permitting her to stay a more healthy life-style amid career-spanning scrutiny over her weight.

Speaking to Kimmel, Winfrey defined that she was initially impressed to lose weight with out the use of weight loss remedy after present process rehabilitation following her 2021 knee surgical procedure. However, docs informed the OWN founder that “obesity is a disease” and her weight will all the time fluctuate.

“I’ve been in the storm of losing the weight, gaining it back. Losing the weight, gaining it back, and what I realised when I listened to what the doctor said, that you are always going to put it back on, and it’s like holding your breath underwater and trying not to rise,” she defined.

Prescription drugs corresponding to Ozempic, Wegovy, and Mounjaro have just lately risen in reputation for his or her off-label weight loss unintended effects. Ozempic is a once-weekly injection used for the remedy of Type 2 diabetes, which works by mimicking a hormone to regulate urge for food and create the sensation of fullness. Wegovy is one other semaglutide injection particularly permitted for the remedy of weight problems and weight loss, whereas Mounjaro is the primary diabetes drug to goal a second hormone, GIP.

Winfrey’s particular, “Shame, Blame and the Weight Loss Revolution,” will focus on the affect of prescription weight loss drugs, in addition to questions and considerations surrounding standard semaglutide or glucagon-like peptide 1 (GLP-1) injections. The particular airs Monday 18 March at 8pm ET on ABC.